What Is Small Airways Disease? Causes and Symptoms

Small airways disease is a condition in which the tiniest breathing tubes in your lungs become inflamed, thickened, or scarred, making it progressively harder to move air in and out. These small airways, generally defined as those less than two millimeters in diameter, sit deep in the lung where they branch into thousands of passages too narrow to see on a standard chest X-ray. Because the damage is so hard to detect early, small airways disease often goes unrecognized until it has already contributed to a measurable drop in lung function, and the list of things that can trigger it is broader than most people realize.

Which Airways Are We Talking About

Your lungs resemble an upside-down tree. The trachea is the trunk, the main bronchi are the large limbs, and with each branching the tubes get narrower and more numerous until you reach the terminal and transitional bronchioles, the smallest conducting passages before air reaches the gas-exchanging sacs called alveoli. These tiny tubes contribute relatively little to airway resistance in a healthy lung because there are so many of them running in parallel. That is part of the problem: you can lose a substantial number of small airways before standard breathing tests pick up anything wrong.

Research using micro-CT imaging of surgical lung specimens has shown that patients with even mild-to-moderate COPD already have significant loss of terminal and transitional bronchioles, sometimes in areas where the surrounding lung tissue still looks structurally normal.¹ In other words, the small airways can be quietly disappearing long before the larger airways or the air sacs show obvious damage. That silent phase is what makes the condition clinically tricky.

What Happens Inside the Small Airways

The core process is chronic inflammation that, over time, reshapes the airway wall itself. In COPD, immune cells such as neutrophils and macrophages accumulate in the small airways and set off a cascade of structural changes: the airway walls thicken, the cells lining the tubes shift toward mucus-producing types, smooth muscle around the airways bulks up, and fibrous tissue can form.² The net effect is airways that are narrower, stiffer, and clogged with more mucus than they should be.

In asthma, the picture overlaps but has its own flavor. The basement membrane beneath the airway lining thickens, the mucus-producing cells multiply, the smooth muscle layer grows, and the composition of the tissue scaffolding around the airways shifts.³ These changes help explain why some people with asthma remain symptomatic even when their large-airway inflammation seems well controlled: the small airways can be a separate battleground that conventional monitoring misses.

Causes and Risk Factors

Small airways disease is not a single diagnosis so much as a pattern of damage that many different insults can produce. The triggers range from the obvious to the surprising.

Smoking and COPD

Cigarette smoke is the most common cause worldwide. The particles and gases in tobacco smoke land preferentially in the small airways and provoke the inflammatory remodeling described above. In COPD, small airway obstruction is considered a fundamental feature of the disease, and it appears years before spirometry readings cross the threshold for a formal diagnosis.⁴ A 15-year prospective cohort study from China found that people with spirometry-defined small airway dysfunction were roughly three times more likely to progress to COPD than those without it, even after adjusting for other risk factors.⁵

Asthma

Small airways disease has been linked to asthma control, severity, and the risk of flare-ups.⁶ People whose asthma preferentially involves the small airways tend to have more frequent exacerbations, respond less well to standard inhalers that deposit medication mainly in larger airways, and score worse on quality-of-life questionnaires. The condition does not only affect people with severe asthma; even those classified as having mild disease can have meaningful small airway involvement that explains lingering symptoms.

Environmental and Occupational Exposures

Wildfire smoke has emerged as a growing concern. The fine particulate matter in wildfire plumes causes oxidative stress, inflammation, and damage to the airway lining, and exposure has been tied to exacerbations of asthma and COPD, increased emergency department visits, and possibly long-term declines in lung function.⁷

Military burn pit exposure provides some of the most direct evidence for toxic inhalation causing small airway scarring. A study of 31 previously healthy, non-smoking soldiers who developed respiratory symptoms during and after deployment found burned metals, carbonaceous materials, and polycyclic aromatic hydrocarbons in their lung biopsies. Histology showed fibrosis and constrictive bronchiolitis, a severe form of small airways disease, and the majority showed airway hyperresponsiveness on testing.⁸ Broader reviews of military airborne hazards have confirmed lung pathologies including small airway scarring, diffuse collagen deposition, and foreign-matter deposition in lung tissue.⁹

Autoimmune Disease

Small airways disease can appear in people with rheumatoid arthritis, even when their chest imaging looks unremarkable. In a study of rheumatoid arthritis patients whose high-resolution CT scans showed no obvious lung disease, roughly 40 percent still had measurable small airway obstruction on spirometry. Having respiratory symptoms, a smoking history, and a disease duration of more than ten years each independently raised the odds of small airway involvement.¹⁰ Other autoimmune conditions, including lupus and Sjögren syndrome, have also been associated with small airway problems, though the data are thinner.

Viral Infections and Transplant-Related Disease

Respiratory viral infections can directly injure the small airways. In lung transplant recipients, community-acquired respiratory viruses are a distinct risk factor for bronchiolitis obliterans syndrome, a devastating form of chronic rejection centered on the small airways.¹¹ Outside the transplant setting, severe lower respiratory infections in infancy, particularly from respiratory syncytial virus, have been associated with reduced lung function lasting into adulthood.¹² The small airways appear to be especially vulnerable during early lung development, and damage sustained in the first years of life may set the stage for chronic airflow limitation decades later.

Symptoms You Might Notice

The frustrating reality of small airways disease is that its symptoms are non-specific. Shortness of breath on exertion is the hallmark, but that describes dozens of conditions. A persistent dry cough, wheezing that standard bronchodilators don’t fully relieve, exercise intolerance that seems out of proportion to what larger-airway tests suggest, and a sense that you cannot empty your lungs completely are all common complaints. Some people describe a chest tightness that lingers between asthma attacks or COPD exacerbations and never fully goes away.

What distinguishes small airways disease from a simple “bad cold that won’t quit” is usually the pattern over time: symptoms that creep in gradually, worsen with activity, and do not respond as well as expected to medications aimed at the larger airways. In the burn-pit exposure cohort mentioned earlier, previously fit soldiers found themselves unable to complete physical tasks they had handled easily before deployment. That kind of new-onset exercise limitation in someone without an obvious explanation is a red flag for small airway involvement.

Why It Is So Hard to Detect

Standard spirometry, the blow-into-a-tube test used in most clinics, mainly measures airflow through the larger airways. The classic numbers that doctors look at, FEV1 and FVC, can stay in the normal range while small airways are already damaged. A measurement called FEF 25-75%, which captures airflow during the middle portion of a forced exhalation and is thought to reflect small airway function, has been studied for decades, but clinicians have been cautious about relying on it because it is highly variable from one effort to the next and its normal range is wide.⁴ Some researchers argue it still has predictive value when interpreted carefully; others maintain it adds little to standard measures.¹³ The debate remains unresolved, and in practice many pulmonologists treat a low FEF 25-75% as a clue worth following up rather than a definitive diagnosis.

Newer tools are filling the gap. Impulse oscillometry measures airway resistance by sending gentle sound waves into the lungs during normal breathing rather than requiring a forced exhalation. It can pick up increased resistance in the small airways before spirometry detects anything.¹⁴ Multiple-breath nitrogen washout is another technique that detects uneven ventilation in the lung periphery, which is a hallmark of small airway damage.¹⁵ Neither test is standard in every clinic, but both are increasingly available in pulmonary function labs.

Exhaled nitric oxide testing offers another window. A measure called the concentration of alveolar nitric oxide, or CANO, reflects inflammation deep in the lungs. In one study of stable asthma patients, CANO was strongly correlated with small airway dysfunction as measured by spirometry, and a cutoff value showed good accuracy for identifying those with small airway problems.¹⁶

CT-Based Imaging and Parametric Response Mapping

Perhaps the most promising development is the use of paired inspiratory and expiratory CT scans analyzed by a technique called parametric response mapping, or PRM. This approach compares each tiny volume element (voxel) of lung tissue between full inhalation and full exhalation and classifies it as normal, emphysematous, or trapped air indicative of functional small airways disease. In COPD patients, the amount of lung classified as having functional small airway disease by PRM is substantially higher than in people without COPD and increases with disease severity.¹⁷

Longitudinal data show that PRM-measured small airway disease also predicts future lung function decline. Over six years of follow-up, every additional ten percent of lung affected by functional small airway disease on PRM was associated with faster yearly drops in both FEV1 and FVC.¹⁸ That finding matters because it means imaging can identify people at risk of accelerated decline, potentially guiding earlier and more aggressive treatment.

One limitation of PRM has been the need for both an inspiratory and an expiratory scan, which doubles the radiation dose and requires patient cooperation. A deep learning method has now been developed that generates PRM-like maps from a single inspiratory CT scan. In testing, this approach was able to stratify small airway disease severity even in individuals whose standard spirometry was still normal.¹⁹ If validated in larger populations, this could make routine screening for small airway disease far more practical.

How Small Airways Disease Progresses

Left unchecked, small airways disease tends to be a one-way street. The 15-year Chinese cohort study found that people whose small airways were already dysfunctional at baseline lost lung function faster over time and were nearly three times as likely to develop spirometry-defined COPD as healthy controls.⁵ This suggests that small airways disease is not just an early marker of COPD but a driving force in its development. Identifying it earlier could, in theory, open a window for intervention before the damage becomes irreversible.

In asthma, the stakes are different but still significant. Persistent small airway inflammation contributes to the phenomenon of asthma that remains poorly controlled despite escalating doses of standard therapy. Patients may be labeled as having “difficult-to-treat” asthma when the real issue is that their medication never reaches the inflamed peripheral airways. Recognizing this pattern can change the treatment approach entirely.

Treatment Approaches

Because the small airways are so deep in the lung, getting medication to them is a genuine pharmacological challenge. Standard metered-dose inhalers and dry powder inhalers produce particles that tend to deposit in the mouth, throat, and larger airways, with only a fraction reaching the periphery. Extrafine-particle inhalers, which generate aerosol droplets small enough to penetrate beyond the large airways, were developed specifically to address this gap. A combination of beclomethasone and formoterol in an extrafine formulation has been shown to achieve more uniform distribution throughout the respiratory tree, including the peripheral airways.²⁰ Studies suggest that extrafine inhaled corticosteroids can achieve higher peripheral lung deposition and improve asthma control in patients with small airway involvement.²¹ In COPD, extrafine formulations combining an inhaled corticosteroid with a long-acting bronchodilator have been explored for their ability to reach the small airways where inflammation is most active.²²

Beyond inhalers, a recent review highlights several strategies being studied for small airway disease in COPD. Smoking cessation remains the single most important intervention, and there is evidence suggesting it may actually reverse some degree of small airway dysfunction. Pulmonary rehabilitation, which combines exercise training, education, and behavioral support, improves symptoms, exercise tolerance, and quality of life while reducing exacerbation frequency. For patients with type 2 inflammatory airway disease, the biologic dupilumab has shown promise in improving small airway function.²³ The framing of small airways disease as a “treatable trait” rather than an inevitable consequence of COPD or severe asthma represents a shift in how clinicians are approaching the problem.

When Small Airways Disease Shows Up Without a Clear Diagnosis

One of the more perplexing clinical scenarios is the patient whose standard lung function tests are normal, whose chest imaging looks clean, and who still reports persistent breathlessness or cough. Some of these people turn out to have isolated small airway dysfunction that falls below the detection threshold of conventional tools. The gap between what patients experience and what basic tests can measure has been a source of frustration for both patients and doctors for decades.

This is especially relevant for veterans exposed to burn pits, wildfire firefighters, industrial workers in dusty environments, and people with autoimmune diseases who develop unexplained respiratory symptoms. If standard spirometry comes back normal, the investigation often stops. Advocating for additional testing, whether oscillometry, nitrogen washout, or CT-based imaging, can make the difference between a missed diagnosis and a targeted treatment plan. As the newer diagnostic tools become more widely available, this diagnostic blind spot is likely to shrink, though for now it remains one of the most common ways small airways disease slips through the cracks.